Observational study of healthcare workers' immunity to COVID-19
Health Care Workers Cohort Study in the EuCARE Project (EuCARE-HCW)
Euresist Network GEIE · NCT05534009
This study looks at how long and how well healthcare workers' immunity to COVID-19 lasts after vaccination or infection, while also checking if new virus variants can dodge that immunity.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Euresist Network GEIE (other) |
| Locations | 7 sites (Düsseldorf and 6 other locations) |
| Trial ID | NCT05534009 on ClinicalTrials.gov |
What this trial studies
The EuCARE-HCW study is an observational multicentre project that collects both retrospective and prospective data from healthcare workers who have either been vaccinated against COVID-19 or have had a confirmed SARS-CoV-2 infection. Participants will provide biological samples periodically over 12-24 months to analyze the impact of different viral variants on immunity. The study aims to understand the duration and breadth of immunity following vaccination and natural infection, as well as the potential for vaccine escape by various SARS-CoV-2 variants. This research involves collaboration across eight countries, enhancing the diversity of data collected.
Who should consider this trial
Good fit: Ideal candidates for this study are adult healthcare workers over 18 years old with documented vaccination or SARS-CoV-2 infection status.
Not a fit: Patients who do not work in healthcare or do not have a history of vaccination or SARS-CoV-2 infection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of COVID-19 vaccines and natural immunity, potentially guiding future vaccination strategies.
How similar studies have performed: Other studies have shown success in analyzing immunity to COVID-19 variants, making this approach both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: The study subjects will be selected based on the following inclusion criteria: 1. Adult (\>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status. 2. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA 3. Having a signed informed consent when required by ethical approval Exclusion Criteria: NONE
Where this trial is running
Düsseldorf and 6 other locations
- Heinrich Heine university — Düsseldorf, Germany (RECRUITING)
- Azienda Socio-Sanitaria Territoriale Santi Paolo e Carlo — Milan, Italy (RECRUITING)
- Ieo Istituto Europeo Di Oncologia — Milan, Italy (RECRUITING)
- Viesoji Istaiga Vilniaus Uiversiteto Ligoninė Santaros klinikos — Vilnius, Lithuania (RECRUITING)
- Hospital Juan Ghaham Casasus — Villahermosa, Mexico (RECRUITING)
- Centro Hospitalar de Lisboa Ocidental — Lisbon, Portugal (RECRUITING)
- Bach Mai Hospital — Hanoi, Vietnam (RECRUITING)
Study contacts
- Study coordinator: FRANCESCA INCARDONA, DR
- Email: francesca.incardona@euresist.org
- Phone: +393356112830
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COVID-19